FDA's proactive role in the development of an artificial pancreas for the treatment of diabetes mellitus

One of the critical path initiatives of the Food and Drug Administration (FDA) is to accelerate the development and availability of a safe and effective artificial pancreas for the treatment of diabetes mellitus. The FDA has established a multidisciplinary group of scientists and clinicians, in part...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today. Technologies 2007, Vol.4 (1), p.25-28
Main Authors: Pinkos, Arleen, Arreaza-Rubin, Guillermo, Heetderks, William J., Irony, Ilan, Joffe, Hylton V., Schneider, Bruce, Zimliki, Charles L.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:One of the critical path initiatives of the Food and Drug Administration (FDA) is to accelerate the development and availability of a safe and effective artificial pancreas for the treatment of diabetes mellitus. The FDA has established a multidisciplinary group of scientists and clinicians, in partnership with the National Institutes of Health (NIH), to address the clinical, scientific and regulatory challenges related to this unique medical product. Janet Woodcock – Food and Drug Administration, Rockville, MD, USA
ISSN:1740-6749
1740-6749
DOI:10.1016/j.ddtec.2007.10.007